TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator-Reference-Cited by-同舟云学术

TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator

Published:2002-03 Issue:3 Volume:16 Page:479-492
ISSN:1074-7613
Container-title:Immunity
language:en
Short-container-title:Immunity

Author:

Migone Thi-Sau,Zhang Jun,Luo Xia,Zhuang Li,Chen Cecil,Hu Bugen,Hong June S.,Perry James W.,Chen Su-Fang,Zhou Joe X.H.,Cho Yun Hee,Ullrich Stephen,Kanakaraj Palanisamy,Carrell Jeffrey,Boyd Ernest,Olsen Henrik S.,Hu Gang,Pukac Laurie,Liu Ding,Ni Jian,Kim Sunghee,Gentz Reiner,Feng Ping,Moore Paul A.,Ruben Steve M.,Wei Ping

Publisher

Elsevier BV

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference28 articles.

1. Apoptosis control by death and decoy receptors;Ashkenazi;Curr. Opin. Cell Biol.,1999

2. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster;Bai;Proc. Natl. Acad. Sci. USA,2000

3. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95);Bodmer;Immunity,1997

4. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95;Chinnaiyan;Science,1996

5. In vivo inhibition of fas ligand-mediated killing by TR6, a fas ligand decoy receptor;Connolly;J Pharmacol Exp. Ther.,2001

Cited by 547 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD;Gut;2024-09-11

2. Limosilactobacillus reuteripromotes the expression and secretion of enteroendocrine- and enterocyte-derived hormones;2024-08-31

3. TL1A priming induces a multi-cytokine Th9 cell phenotype that promotes robust allergic inflammation in murine models of asthma;Mucosal Immunology;2024-08

4. Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway;International Immunopharmacology;2024-08

5. Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8⁺T cells and inhibited tumor growth;Journal for ImmunoTherapy of Cancer;2024-08